Contribution: Industrial Research Assistance Program – Contributions to Firms
Virocarb Inc.
$350,816.00
Determination of oral efficacy GPS-491 in an animal model of SARS-CoV-2
FY 2021-22 · 2021-12-01
Summary
ViroCarb has developed, in collaboration with leading academics in molecular genetics, functional proteomics, and medicinal chemistry, a paradigm-shifting drug platform to stop the replication of multiple viruses, by targeting a cellular function essential for their propagation in cells (RNA processing). Our preclinical drug candidate GPS-491 is highly effective in inhibiting the replication of multiple viruses including SARS-CoV2 and other members of the coronavirus family in human cells. Our goal is to conduct in vivo efficacy studies of our drug candidate in a COVID-19 model of infection in ACE2 transgenic mice, as well as to conduct target validation studies to support the clinical development of a new therapy for COVID-19.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
815903208
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-12-01 | 2021-22 | $160,500.00 |
| 1 | 2021-12-01 | 2021-22 | $160,500.00 |
| 2 | 2021-12-01 | 2021-22 | $350,816.00 |
| 3 | 2021-12-01 | 2021-22 | $350,816.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 60 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 60 jours.
Agreement End Date
2024-02-29
Agreement Number
987152
Agreement Start Date
2021-12-01
Agreement Title
Determination of oral efficacy GPS-491 in an animal model of SARS-CoV-2
Agreement Title (French)
Déterminer l'efficacité de l'administration orale de GPS-491 dans un modèle animal d'infection à SRAS-CoV-2
Agreement Type
Contribution
Agreement Value
$350,816.00
Amendment Date
2023-12-11
Amendment Number
3
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
ViroCarb has developed, in collaboration with leading academics in molecular genetics, functional proteomics, and medicinal chemistry, a paradigm-shifting drug platform to stop the replication of multiple viruses, by targeting a cellular function essential for their propagation in cells (RNA processing). Our preclinical drug candidate GPS-491 is highly effective in inhibiting the replication of multiple viruses including SARS-CoV2 and other members of the coronavirus family in human cells. Our goal is to conduct in vivo efficacy studies of our drug candidate in a COVID-19 model of infection in ACE2 transgenic mice, as well as to conduct target validation studies to support the clinical development of a new therapy for COVID-19.
Description (French)
ViroCarb a mise au point, en collaboration avec des universitaires de premier plan dans les domaines de la génétique moléculaire, de la protéomique fonctionnelle et de la chimie médicinale, une plateforme médicamenteuse permettant d'arrêter la réplication de plusieurs virus, en ciblant une fonction cellulaire essentielle à leur propagation dans les cellules (traitement de l'ARN). Notre médicament candidat préclinique, GPS-491, est très efficace pour inhiber la réplication de plusieurs virus dans les cellules humaines, dont le SARS-CoV2 et d'autres membres de la famille des coronavirus. Notre objectif est de mener des études d'efficacité in vivo de notre médicament candidat dans un modèle d'infection COVID-19 chez des souris transgéniques ACE2, ainsi que de mener des études de validation des cibles pour soutenir le développement clinique d'un nouveau traitement de la COVID-19.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Etobicoke--Lakeshore
Federal Riding (French)
Etobicoke--Lakeshore
Federal Riding Number
35028
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
815903208
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Virocarb Inc.
Recipient Postal Code
M8V 3Y3
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2021-2022-Q4-987152
